Members-only Site   |   Print Page   |   Contact Us   |   Sign In   |   Register
IACP Meets with the Government Accountability Office to discuss Animal Drug Compounding
Share |

At the request of the Government Accountability Office (GAO), IACP met with staff from the GAO on August 13th to discuss animal drug compounding. It is expected that the Agency will release a report based upon the Agency’s meetings and discussions with all opponents and proponents of compounding for animal use.  

The lengthy meeting centered around questions from GAO including the
U.S. Food & Drug Administration's (FDA’s) authority to oversee animal drug compounding; accreditation of veterinary pharmacies; safety and effectiveness of drug compounding for animal use; state regulatory practices regarding compounding for animal use; adverse events reporting and data available on such events; and drug approval process at FDA for animal drug compounding.  

As IACP previously reported, FDA stated within its annual Appropriations justification to Congress, that funds are needed by the Agency to develop guidance addressing animal compounding. With increased efforts by FDA to address animal compounding, IACP has worked with the
American Veterinary Medical Association (AVMA) to establish Veterinary Task Forces that will work to address any regulatory and/or legislative efforts to restrict animal compounding. IACP has met with AVMA and the AVMA Veterinary Task Force several times in the past months and looks forward to working with GAO, Congress, AVMA, and all stakeholders to provide insight into the benefit that animal compounding provides.

Association Management Software Powered by YourMembership  ::  Legal